DSM announces expiration of waiting period under Hart-Scott-Rodino Act
(Thomson Reuters ONE) -
Royal DSM (NYSE Euronext: DSM KON), the global Life Sciences and Materials
Sciences company, announced today the expiration of the mandatory waiting period
under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, for
its previously announced tender offer for all outstanding shares of common stock
of Kensey Nash Corporation (NASDAQ: KNSY) at a price of $38.50 per share (the
"Offer"). This condition of the Offer is thus satisfied.
The Offer remains subject to the satisfaction of certain other conditions. The
Offer is scheduled to expire at 12:00 midnight (New York City time) at the end
of Monday, June 18, 2012, unless the Offer is extended.
Kensey Nash
Kensey Nash is a medical device company primarily focused on regenerative
medicine utilizing its proprietary collagen and synthetic polymer technology.
The company is recognized as a leader for innovative product development and
unique technology in the field of resorbable biomaterials. The company has an
extensive range of products, which are sold through strategic partners in
multiple medical markets, including the cardiology, orthopedic, sports medicine,
spine, trauma, craniomaxillofacial and general surgery markets. For more
information, visit http://www.kenseynash.com.
DSM - Bright Science. Brighter Living.(TM)
Royal DSM is a global science-based company active in health, nutrition and
materials. By connecting its unique competences in Life Sciences and Materials
Sciences DSM is driving economic prosperity, environmental progress and social
advances to create sustainable value for all stakeholders. DSM delivers
innovative solutions that nourish, protect and improve performance in global
markets such as food and dietary supplements, personal care, feed,
pharmaceuticals, medical devices, automotive, paints, electrical and
electronics, life protection, alternative energy and bio-based materials. DSM's
22,000 employees deliver annual net sales of around ?9 billion. The company is
listed on NYSE Euronext. More information can be found at www.dsm.com.
For more information:
DSM Corporate Communications DSM Investor Relations
Herman Betten Hans Vossen
tel. +31 (0) 45 5782017 tel. +31 (0) 45 5782864
fax +31 (0) 45 5740680 fax +31 (0) 10 4590275
e-mail media.relations(at)dsm.com e-mail investor.relations(at)dsm.com
Kensey Nash
Joseph W. Kaufmann
Tel. +1 484 713 2100
Press release-pdf:
http://hugin.info/130663/R/1617576/516198.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DSM N.V. via Thomson Reuters ONE
[HUG#1617576]
Unternehmensinformation / Kurzprofil:
Datum: 06.06.2012 - 08:16 Uhr
Sprache: Deutsch
News-ID 153560
Anzahl Zeichen: 3395
contact information:
Town:
Heerlen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 114 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DSM announces expiration of waiting period under Hart-Scott-Rodino Act"
steht unter der journalistisch-redaktionellen Verantwortung von
DSM N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
